---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Conclusions"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Conclusions. 1 evidence topic quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary/conclusions"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

- Status: envudeucitinib is “an investigational drug, not reviewed or approved by any regulatory agency”, and Alumis plans to submit its New Drug Application to the FDA for moderate-to-severe plaque psoriasis in the fourth quarter of 2026. The Alumis Form 10-Q for the third quarter of 2026 states that cash, cash equivalents, and marketable securities of $431.3 million as of September 30, 2026 will not be sufficient to meet its operating and capital requirements for at least 12 months and that there is “substantial doubt about the Company’s ability to continue as a going concern”. The third-quarter results press release states that the same resources as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.
- ONWARD1 and ONWARD2: in these phase 3 trials, participants were randomized to envudeucitinib 40 mg twice daily, placebo, or apremilast. At week 16, PASI 75 was achieved by 76.5% of envudeucitinib, 18.7% of placebo, and 44.4% of apremilast participants in ONWARD1 and by 70.4%, 13.7%, and 38.6% in ONWARD2. At week 24, PASI 100 was achieved by 41.0% of envudeucitinib and 8.5% of apremilast participants in ONWARD1 and by 39.5% and 13.0% in ONWARD2. In the pooled safety population through week 16, TEAEs occurred in 58.9%, 37.6%, and 50.9% of envudeucitinib, placebo, and apremilast participants, SAEs in 2.1%, 1.1%, and 1.1%, TEAEs leading to discontinuation in 3.4%, 1.6%, and 2.1%, and acne in 6.0%, 0.7%, and 0.7%.
- ONWARD3: in the long-term extension, a non-responder imputation analysis of 773 participants from the envudeucitinib arms who received up to 48 weeks of continuous treatment reported PASI 90 in 75% and PASI 100 in 54%. A separate integrated non-responder imputation analysis of the 890 participants originally randomized to envudeucitinib, including those who did not enter ONWARD3, reported 66% and 47% after 48 weeks.
- STRIDE: in the phase 2 trial, 228 participants were randomized to placebo or one of five envudeucitinib doses, and PASI 75 at week 12 was achieved by 64% with 40 mg BID and 0% with placebo (P < .0001). In the open-label extension, after 52 weeks of 40 mg twice daily, the article text reports PASI 75 in 78%, PASI 90 in 61%, and PASI 100 in 39%; its efficacy table gives PASI 100 as 38.8% in the original 40 mg BID group and 32.6% in the overall 40 mg BID group. In the extension safety analysis set (164 participants), 65.9% had at least one TEAE and 3.7% discontinued study drug due to AEs.
- Comparators and comparison evidence: the oral comparators in the report are deucravacitinib, apremilast, and icotrokinra, each with a U.S. prescribing information, and zasocitinib, whose NDA the FDA accepted under Priority Review with a PDUFA target action date in the first quarter of calendar year 2027. The active comparator of ONWARD1 and ONWARD2 is apremilast, and the report holds no trial of envudeucitinib against deucravacitinib, icotrokinra, zasocitinib, or a biologic. A review whose medical writing Alumis funded states that direct and formal indirect comparisons of oral agents “are not presently available”. Icotrokinra and zasocitinib have each been compared with deucravacitinib: week 16 PASI 90 was 55% with icotrokinra and 30% with deucravacitinib in Trial PSO-1 of the icotrokinra label, and week 16 PASI 100 was 36.5% with zasocitinib and 13.9% with deucravacitinib in LATITUDE Atlas. The Alumis corporate presentation sets the ONWARD week 24 PASI 100 rates (41.0% and 39.5%) beside those of icotrokinra (41.5% and 33.2%) and zasocitinib (42.3% and 32.1%) in a “retrospective post hoc cross-trial comparison” whose results it states “may not be directly comparable”.
- Evidence gaps: the ONWARD1, ONWARD2, and ONWARD3 results come from company press releases, company presentations, and congress posters; the report holds no peer-reviewed ONWARD publication, and the ClinicalTrials.gov records of ONWARD1 and ONWARD2 read “No Results Posted”. The report holds no participant disposition data for ONWARD1 or ONWARD2 and no subgroup results for envudeucitinib. Four completed studies (a QT study, a hepatic impairment study, a renal impairment study, and a tablet and liquid relative bioavailability study) have no posted results. A narrative review states that long-term safety data for zasocitinib and envudeucitinib “are not yet available”, and Alumis plans to report two-year phase 2 safety data in the fourth quarter of 2026.
- Price and economic analyses: the report records no price, budget impact model, or published economic analysis for envudeucitinib. Package prices of the oral comparators include a Sotyktu WAC price of 7135.55 in the Texas DSHS 2026 annual WAC report, an ICOTYDE 200mg 30-tablet WAC at introduction of 8285.0000 on 2026-03-18 in the California HCAI new prescription drugs file, and an Otezla 30mg 60 pack price of 5589.89 effective 01/07/2026 in the California HCAI WAC increase file.

Source: [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/); [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm); [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm); [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf); [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm); [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm); [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext); [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf); [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf); [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf); [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/); [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/); [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/); [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2); [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4); [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738); [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579); [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634); [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774); [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858); [Texas DSHS 2026 annual WAC report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx); [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI prescription drug WAC increases, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
